Tourmaline Bio Inc reports results for the quarter ended June 30 - Earnings Summary
I'm PortAI, I can summarize articles.
Tourmaline Bio IncQ) reported a quarterly adjusted loss of 90 cents per share for the quarter ended June 30, compared to a loss of 68 cents in the same quarter last year. The reported revenue was zero, aligning with analyst expectations. The company incurred a quarterly loss of $23.09 million. Tourmaline Bio shares rose 34.3% this quarter, with a current average analyst rating of "buy". The median 12-month price target is $56.50, approximately 62% above the last closing price of $21.48.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments